Understand the source comparison
Dosing Protocols: Single vs Repeat Administration
Acute single-dose studies using PE-22-28 demonstrate rapid TREK-1 blockade within 30–60 minutes post-injection, but behavioural antidepressant effects require repeated administration over 7–28 days. This delay mirrors clinical antidepressant onset and reflects
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute single-dose studies using PE-22-28 demonstrate rapid TREK-1 blockade within 30–60 minutes post-injection, but behavioural antidepressant effects require repeated administration over 7–28 days. This delay mirrors clinical antidepressant onset and reflects the time required for BDNF-mediated synaptogenesis and dendritic remodelling. Single-dose protocols at 1.0 mg/kg show transient reductions in stress-induced corticosterone but no lasting behavioural change.
- Repeated-dose protocols follow one of two designs: daily administration at 0.3–0.5 mg/kg, or twice-daily administration at 0.1–0.25 mg/kg to maintain more stable plasma levels given the peptide's 4–6 hour half-life. The twice-daily approach theoretically sustains TREK-1 inhibition across circadian cycles, but published efficacy data predominantly use once-daily protocols. Suggesting that peak receptor blockade during the active phase (when BDNF transcription is naturally elevated) may be sufficient.
- Dose escalation is rarely employed in PE-22-28 research because the peptide does not induce tolerance or receptor downregulation over 28-day treatment periods. Starting at 0.5 mg/kg and maintaining that dose throughout the study produces consistent plasma exposure without compensatory neuroadaptations. In contrast, SSRI protocols often require 4–6 weeks before behavioural effects emerge due to serotonin autoreceptor desensitisation. PE-22-28's direct action on ion channels bypasses this lag.